-
1 Comment
Lipocine Inc is currently in a long term downtrend where the price is trading 9.8% below its 200 day moving average.
From a valuation standpoint, the stock is 78.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 286.7.
Lipocine Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 37.0% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 11.4% to $-4M since the same quarter in the previous year.
Based on the above factors, Lipocine Inc gets an overall score of 1/5.
| ISIN | US53630X1046 |
|---|---|
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | 0.0 |
|---|---|
| Target Price | 6.75 |
| Beta | 1.51 |
| Market Cap | 19M |
| Dividend Yield | None |
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LPCN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
